These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12408135)

  • 1. Reputations at stake.
    New Sci; 2002 Mar; 173(2334):16. PubMed ID: 12408135
    [No Abstract]   [Full Text] [Related]  

  • 2. Corporate science v the right to know: is the rise of the private sector bringing down a cloak of secrecy?
    Concar D
    New Sci; 2002 Mar; 173(2334):14-6. PubMed ID: 12408133
    [No Abstract]   [Full Text] [Related]  

  • 3. Spitzer sues drug giant for deceiving doctors.
    Wadman M
    Nature; 2004 Jun; 429(6992):589. PubMed ID: 15190317
    [No Abstract]   [Full Text] [Related]  

  • 4. Putting GlaxoSmithKline to the test over paroxetine.
    Doshi P
    BMJ; 2013 Nov; 347():f6754. PubMed ID: 24222673
    [No Abstract]   [Full Text] [Related]  

  • 5. Gagged and bound.
    New Sci; 2002 Mar; 173(2334):15. PubMed ID: 12408134
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-company data vaults to be opened.
    Cressey D
    Nature; 2013 Mar; 495(7442):419-20. PubMed ID: 23538802
    [No Abstract]   [Full Text] [Related]  

  • 7. Is GSK guilty of fraud?
    Lancet
    Lancet; 2004 Jun; 363(9425):1919. PubMed ID: 15194246
    [No Abstract]   [Full Text] [Related]  

  • 8. Court filing makes public my previously suppressed analysis of Paxil's effects.
    Breggin PR
    Ethical Hum Psychol Psychiatry; 2006; 8(1):77-84. PubMed ID: 16862720
    [No Abstract]   [Full Text] [Related]  

  • 9. Public access versus proprietary rights in genomic information: what is the proper role of intellectual property rights?
    Mueller JM
    J Health Care Law Policy; 2003; 6(2):222-40. PubMed ID: 15017961
    [No Abstract]   [Full Text] [Related]  

  • 10. Compounding risks to patients: selective disclosure is not an option.
    McGoey L
    Am J Bioeth; 2009 Aug; 9(8):35-6. PubMed ID: 19998156
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
    Cohen K; Cormier JW; Davar MV
    J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
    [No Abstract]   [Full Text] [Related]  

  • 12. British rethinking test rules after drug trial nearly kills 6.
    Rosenthal E
    N Y Times Web; 2006 Apr; ():A1, A6. PubMed ID: 16642579
    [No Abstract]   [Full Text] [Related]  

  • 13. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glaxo agrees to post results of drug trials on web site.
    Harris G
    N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364
    [No Abstract]   [Full Text] [Related]  

  • 15. College was right not to disclose deliberations about chronic fatigue treatment trial, tribunal rules.
    Dyer C
    BMJ; 2013 Aug; 347():f5355. PubMed ID: 23996378
    [No Abstract]   [Full Text] [Related]  

  • 16. [Beyond "data sharing"].
    Lamarca R; Herrera D
    Med Clin (Barc); 2015 Jun; 144(12):548-9. PubMed ID: 25843632
    [No Abstract]   [Full Text] [Related]  

  • 17. British MRC reprimanded over clinical test record.
    Dickson D
    Nat Med; 1998 Jul; 4(7):752. PubMed ID: 9662351
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicine. Moving toward transparency of clinical trials.
    Zarin DA; Tse T
    Science; 2008 Mar; 319(5868):1340-2. PubMed ID: 18323436
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
    Vedantam S
    Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.